---
title: "Obefazimod (ABX464) in Ulcerative colitis: Generic, brand name and therapeutic class of product"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Generic, brand name and therapeutic class of product. Topics: Generic name, chemical name, and identifiers; Development code: ABX464; Therapeutic class: oral small molecule miR-124 enhancer; Manufacturer: Abivax. 4 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/generic-brand-name-and-therapeutic-class-of-product"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Generic, brand name and therapeutic class of product

<a id="heading-2.1.2.1"></a>

## 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

### Generic name, chemical name, and identifiers

| Field | Quoted record |
| --- | --- |
| International nonproprietary name (Latin) | “obefazimodum” |
| International nonproprietary name (English) | “obefazimod” |
| Chemical name | “8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine” |
| Functional description | “immunomodulator” |
| Molecular formula | “C16H10ClF3N2O” |
| CAS registry number | “1258453-75-6” |
| INN list | “Proposed INN: List 125” |

Source: [WHO Drug Information (2021)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl125.pdf)

<a id="topic-2.1.2.1-2"></a>

### Development code: ABX464

> “Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.”

Source: [Abivax first half 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-business-updates-and-first-half-2026-financial)

> “ABX464 (obefazimod) is a small molecule that selectively upregulates miR-124 in immune cells.”

Source: [Vermeire et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36075249/)

<a id="topic-2.1.2.1-3"></a>

### Brand name

No evidence found.

<a id="topic-2.1.2.1-4"></a>

### Therapeutic class: oral small molecule miR-124 enhancer

> “Obefazimod is an investigational, orally administered, once-daily therapy, which we believe has the potential to be a differentiated treatment option for inflammatory bowel diseases. It is the first and only molecule that enhances the expression of microRNA-124 (miR-124), a natural regulator of the inflammatory response.”
> “If approved, this therapy has the potential to establish a new therapeutic class currently being referred to as miR-124 enhancers.”

Source: [Abivax obefazimod web page](https://www.abivax.com/our-science/obefazimod/)

> “Obefazimod is an oral small molecule that selectively enhances the expression of a single micro-RNA (miRNA), miR-124.”

Source: [Vermeire et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12124117/)

> “Obefazimod (ABX464) is a first-in-class, oral small molecule that enhances microRNA-124 (miR-124) biogenesis, suppressing STAT3 and CCL2 signaling, reducing Th17 polarization and macrophage activation.”

Source: [Parra-Izquierdo et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42777529/)

<a id="topic-2.1.2.1-5"></a>

### Manufacturer: Abivax

> “Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.”

Source: [Abivax first half 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-business-updates-and-first-half-2026-financial)

> “Achieving alignment with the FDA on our NDA submission strategy marks an important milestone as we prepare to submit Abivax's first New Drug Application for obefazimod.”

Source: [Abivax press release, pre-NDA interaction with the FDA (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-pre-nda-interaction-fda-obefazimod)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
